Form 4: Amylyx Co-CEO Sells Shares for Tax Obligations

Amylyx Pharmaceuticals Co-CEO Joshua B. Cohen sold 29,933 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Joshua B. Cohen, Co-Chief Executive Officer and Director of Amylyx Pharmaceuticals, Inc., reported the sale of common stock.
• A total of 29,933 shares were sold on September 30, 2025.
• The sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• These sales were automatic and not at the discretion of Mr. Cohen.
• The shares were sold at weighted average prices of $14.3433 for 29,733 shares and $14.9975 for 200 shares.
• Following these transactions, Mr. Cohen beneficially owns 3,325,347 shares of Amylyx common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations related to RSU vesting, which is a neutral event for company sentiment.

Future Outlook

No future outlook or guidance is provided in this Statement of Changes in Beneficial Ownership.

Management Comments

• The sales were automatic and not at the discretion of the Reporting Person, representing shares required to be sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

This is a routine insider transaction for tax purposes and does not provide specific industry context or implications for broader industry trends.

Stakeholder Impact

• Minimal direct impact on shareholders as it's a routine, non-discretionary tax-related sale by an executive, not signaling a change in company outlook or executive confidence.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by Co-CEO Joshua B. Cohen to cover tax withholding obligations upon the vesting of restricted stock units. Such transactions are common and do not typically reflect a change in the executive's confidence in the company or its future prospects. Therefore, this filing alone does not provide a basis for a change in investment recommendation, and a 'hold' stance is maintained, pending further fundamental analysis.

Keywords

Amylyx Pharmaceuticals, AMLX, Joshua B. Cohen, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding